Tuesday, August 15, 2017 4:12:29 PM
MRNS is not about the rare pediatric indications imho. It is about everything that Sage is doing. And Sage is doing a lot. MRNS could profit from Sage's data readouts in PPD and also SRSE (they have plans for both indications) and also from the poc studys in other indications (lots of data readouts in H2).
They also could surprise everyone with the recently started study in ppd which uses the new IV formulation and will have results later this year. Both IV formulations - 547 and ganaxalone use captisol from LGND. So there is a chance that problems with bioavailabilty are solved.
Nevertheless MRNS is high risk and so i already started selling some and will continue selling if price goes up.
They also could surprise everyone with the recently started study in ppd which uses the new IV formulation and will have results later this year. Both IV formulations - 547 and ganaxalone use captisol from LGND. So there is a chance that problems with bioavailabilty are solved.
Nevertheless MRNS is high risk and so i already started selling some and will continue selling if price goes up.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
